4563 Stock Overview
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
AnGes, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥50.00 |
52 Week High | JP¥143.00 |
52 Week Low | JP¥49.00 |
Beta | 0.57 |
1 Month Change | -28.57% |
3 Month Change | -30.56% |
1 Year Change | -51.92% |
3 Year Change | -94.70% |
5 Year Change | -94.10% |
Change since IPO | -97.14% |
Recent News & Updates
Recent updates
Shareholder Returns
4563 | JP Biotechs | JP Market | |
---|---|---|---|
7D | -3.8% | -6.2% | -4.7% |
1Y | -51.9% | -30.4% | 26.3% |
Return vs Industry: 4563 underperformed the JP Biotechs industry which returned -30.4% over the past year.
Return vs Market: 4563 underperformed the JP Market which returned 26.3% over the past year.
Price Volatility
4563 volatility | |
---|---|
4563 Average Weekly Movement | 6.1% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 4.1% |
10% most volatile stocks in JP Market | 8.2% |
10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4563's share price has been volatile over the past 3 months.
Volatility Over Time: 4563's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 145 | Ei Yamada | www.anges.co.jp |
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University.
AnGes, Inc. Fundamentals Summary
4563 fundamental statistics | |
---|---|
Market cap | JP¥10.06b |
Earnings (TTM) | -JP¥7.44b |
Revenue (TTM) | JP¥152.00m |
66.2x
P/S Ratio-1.4x
P/E RatioIs 4563 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4563 income statement (TTM) | |
---|---|
Revenue | JP¥152.00m |
Cost of Revenue | JP¥134.00m |
Gross Profit | JP¥18.00m |
Other Expenses | JP¥7.46b |
Earnings | -JP¥7.44b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
Earnings per share (EPS) | -36.96 |
Gross Margin | 11.84% |
Net Profit Margin | -4,892.76% |
Debt/Equity Ratio | 0% |
How did 4563 perform over the long term?
See historical performance and comparison